ArticleSleep2012
Normal cerebrospinal fluid histamine and tele-methylhistamine levels in hypersomnia conditions.
Article in Sleep, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 98 citations in OpenAlex.
- A quest for a histaminergic or orexinergic biomarker for sudden infant death syndrome.Pediatric research · 2026Article
- The role of histamine in narcolepsy type 1: a narrative review.Frontiers in neurology · 2026Review
- Idiopathic hypersomnia is a 24-hour disorder.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2025Review
- Pathophysiological Models of Hypersomnolence Associated With Depression.Biological psychiatry global open science · 2025Review
- The electroretinography to identify biomarkers of idiopathic hypersomnia and narcolepsy type 1.Journal of sleep research · 2025Article
- Histaminergic System Activity in the Central Nervous System: The Role in Neurodevelopmental and Neurodegenerative Disorders.International journal of molecular sciences · 2024Review
- Diagnostic challenges and burden of idiopathic hypersomnia: a systematic literature review.Sleep advances : a journal of the Sleep Research Society · 2024Article
- Body Weight and Metabolic Rate Changes in Narcolepsy: Current Knowledge and Future Directions.Metabolites · 2022Review
- Alterations in the structural covariance network of the hypothalamus in patients with narcolepsy.Neuroradiology · 2022Article
- Characterization of rapid weight gain phenotype in children with narcolepsy.CNS neuroscience & therapeutics · 2022Article
- Histamine in murine narcolepsy: What do genetic and immune models tell us?Brain pathology (Zurich, Switzerland) · 2022Article
- Changes in Histaminergic System in Neuropsychiatric Disorders and the Potential Treatment Consequences.Current neuropharmacology · 2022Review
- Disrupted nighttime sleep and sleep instability in narcolepsy.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2022Review
- Cerebrospinal Fluid Histamine Levels in Healthy Children and Potential Implication for SIDS: Observational Study in a French Tertiary Care Hospital.Frontiers in pediatrics · 2022Article
- The Histaminergic System in Neuropsychiatric Disorders.Biomolecules · 2021Review
- Article
- Narcolepsy with cataplexy: Does age at diagnosis change the clinical picture?CNS neuroscience & therapeutics · 2020Article
- Excessive daytime sleepiness in narcolepsy and central nervous system hypersomnias.Sleep & breathing = Schlaf & Atmung · 2020Review
- Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment.Nature reviews. Neurology · 2019Review
- Impaired histaminergic neurotransmission in children with narcolepsy type 1.CNS neuroscience & therapeutics · 2019Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
STUDY
objectivesTo determine the activity of cerebral histaminergic system evaluated by CSF levels of histamine (HA) and tele-methylhistamine (t-MHA), its major metabolite, and their relationships with hypocretin-1 levels in a large population of patients with hypersomnia and neurological conditions.
designsensitive liquid chromatographic-electrospray/tandem mass spectrometric assay was developed for the simultaneous quantification of CSF HA and t-MHA.
settingata were collected and CSF hypocretin-1 levels were measured using radioimmunoassay at the Sleep Disorders Center, Montpellier, France. CSF HA and t-MHA were measured in Bioprojet-Biotech, France
participantsOne hundred fourteen unrelated patients with a suspicion of central hypersomnia underwent one night of polysomnography followed by the multiple sleep latency test. Sleep disorders were diagnosed clinically and using sleep studies: narcolepsy-cataplexy NC (n = 56), narcolepsy without cataplexy NwC (n = 27), idiopathic hypersomnia IH (n = 11), secondary narcolepsy (n = 3), and unspecified hypersomnia Uns EDS (n = 17). Fifty neurological patients without daytime sleepiness were included as controls. MEASUREMENTS AND
resultsNo between-hypersomnia group differences were found for CSF HA levels (median 708.62 pM extreme range [55.92-3335.50] in NC; 781.34 [174.08-4391.50] in NwC; 489.42 [177.45-906.70] in IH, and 1155.40 [134.80-2736.59] in Uns EDS) or for t-MHA levels. No association was found between CSF HA, t-MHA, or HA + t-MHA, sleepiness, treatment intake, and frequency of cataplexy. A slight negative correlation was found between age and HA levels. Further adjustment for the age revealed no significant HA levels difference between hypersomnia patients and controls.
conclusionCSF histamine and tele-methylhistamine did not significantly differ between patients with narcolepsy-cataplexy and other etiologies of non-hypocretin-1 deficient central hypersomnias; these measurements, therefore, are not useful in assessing the etiology or severity of centrally mediated hypersomnia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.